Invivyd Management Engages Investors at BioConnect Conference
Invivyd, Inc. has made an exciting announcement, revealing their participation in a significant investor event. The company's management will hold a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference, scheduled for a date in May. The conference will be held in New York, and Invivyd's leadership is eager to share insights directly with investors.
Fireside Chat Highlights
During the fireside chat, which takes place at 11:00 a.m. ET, Invivyd's team will discuss their innovative developments in biopharmaceuticals. They will provide a comprehensive overview of their mission: delivering advanced solutions to combat viral infectious diseases. The conversation is anticipated to explore the state of ongoing projects and the progress towards creating best-in-class antibodies.
Investor Meetings and Engagement
Beyond the fireside chat, Invivyd's management team will host a series of investor meetings throughout the conference. This gives attendees a chance to engage directly with the team, offering a valuable platform for inquiries and discussions. Those interested in securing a meeting are encouraged to reach out via their H.C. Wainwright representatives.
Webcast and Accessibility
For those unable to attend the conference in person, a live webcast of the fireside chat will be made accessible on Invivyd's investor website. The company plans to archive the broadcast for approximately 30 days following the event, ensuring that a wider audience can benefit from the insights shared during the discussion.
About Invivyd, Inc.
Invivyd, Inc. (Nasdaq: IVVD) stands at the forefront of biopharmaceutical innovation. Their primary goal is to protect against serious viral infections, beginning with SARS-CoV-2. To achieve this, Invivyd employs a proprietary integrated technology platform that is unmatched in the industry. This cutting-edge platform allows the company to effectively assess, monitor, develop, and adapt its innovative antibody candidates.
Recent Achievements
Earlier this year, Invivyd received emergency use authorization from the U.S. FDA for one of its monoclonal antibody (mAb) candidates. This milestone showcases the company's commitment to leading advancements in treatment options. With their focus on developing comprehensive viral defense solutions, Invivyd is poised for significant growth as they continue to expand their product pipeline.
Connect with Invivyd
For media inquiries, Invivyd can be reached at (781) 208-1747, and media relations are encouraged to connect via their official media email.
Frequently Asked Questions
What is the purpose of Invivyd's participation at the conference?
Invivyd aims to update investors on their developments in biopharmaceuticals and engage with them about their innovative projects.
How can investors learn more about Invivyd and their technologies?
Investors can visit the investor section on Invivyd's website for detailed information and access to the upcoming webcast.
What recent achievements has Invivyd accomplished?
Invivyd received emergency use authorization from the U.S. FDA for a monoclonal antibody, highlighting their innovative treatment approach.
How can investors contact Invivyd management?
Investors interested in meetings can reach out through their H.C. Wainwright representatives during the conference.
What is Invivyd's focus in the biopharmaceutical industry?
Invivyd focuses on developing protective solutions against viral infectious diseases, leveraging their unique integrated technology platform.
